Scientific videos, interactive websites & academic figures. Bringing compound science to life for patients, physicians & partners.
New York, NY
Joined September 2026
- Tweets94
- Following0
- Followers14
- Likes135
Pinned Tweet
Watch the orange protein approach, then fail to bind.
Daraxonrasib brings cyclophilin A and active RAS together. The resulting complex blocks effector access.
15 seconds inside the mechanism.
Different audiences need different depth. A scientific film provides the overview; an interactive website lets people inspect the mechanism and revisit the evidence. See how that works in our independent CAR-T demo.
cellularstories.com
Fundraising materials need to explain why the science matters—and what the evidence supports. We help biotech leadership make complex mechanisms understandable through films, interactive websites and academic figures.
cellularstories.com
What happens after an antibody-drug conjugate binds its target? Our T-DM1 example follows the next steps inside the cell. Pause, inspect and connect each step with the explanation.
Independent educational demo.
cellularstories.com
Trial education should make the science understandable without promising benefit. We create visual explanations that teams can adapt and review for patients and study sites.
Explore our independent CAR-T demo:
cellularstories.com
A partnering meeting leaves little time to explain unfamiliar science. Give potential partners a clear path through the unmet need, mechanism and evidence—with an interactive example they can revisit.
cellularstories.com
For Medical Affairs, a mechanism visual should help physicians connect the biology with the clinical evidence. We build scientific films, interactive explanations and editable figures around that need.
cellularstories.com
A CAR-T explanation should connect target recognition with what happens next. Watch the interaction, then explore the mechanism at your own pace.
Independent educational demo.
cellularstories.com
How does a vaccine made from your tumor teach T cells what to recognize?
From tumor mutations to mRNA delivery, peptide presentation and immune recognition, in 1:56.
Our full V940 cancer-vaccine animation. Investigational therapy; independent educational visualization.
For biotech teams preparing partner or investor discussions: we turn a lead program’s mechanism and clinical evidence into a scientific film, interactive website and figures.
Send us the program and audience. We can start with a three-scene outline.
cellularstories.com/biotech-…
Direct link to our Biotech leadership page: cellularstories.com/biotech-…
How does a tumor mutation become a target a T cell can recognize?
The one-minute version: tumor sequencing, RNA delivery, translation and peptide presentation.
Our V940 mechanism animation. Investigational therapy; representative molecular structures.
Getting mRNA into a cell is only half the journey. It has to escape the endosome before a ribosome can read it.
Watch the RNA enter, then a separate protein emerge. 22 seconds from our personalized cancer-vaccine animation. Illustrative molecular pathway.
What does it mean to bring two proteins together to interrupt RAS signaling? Explore our 3D explanation of daraxonrasib’s proposed mechanism.
Independent educational demo.
cellularstories.com
A T cell reads a tiny peptide on a cancer cell’s surface.
Three scenes from our new cancer-vaccine study: RNA delivery, ribosome translation and T-cell recognition.
Illustrative science, built in Three.js.
cellularstories.com
Daraxonrasib binds cyclophilin A first. The pair then engages active RAS.
28 seconds from pancreatic tissue to the molecular interaction, with an illustrative tumor response.
Explore it: cellularstories.com/examples…
Interactive version, structures and references:
cellularstories.com/#/storie…
Independent educational illustration. Molecular motion is authored, not a molecular-dynamics simulation.
An antibody-drug conjugate has to reach the tumor before it can act inside a cell. Follow T-DM1 from blood vessel to tumor in our interactive explanation.
Independent educational demo.
cellularstories.com
This drug recruits one protein to block another.
Daraxonrasib brings cyclophilin A and active RAS together, obstructing the interaction with downstream effectors.
20 seconds inside the mechanism. Independent illustration.
cellularstories.com/examples…
The six-panel view: drug + cyclophilin A + active RAS form a complex that obstructs effector binding.
The molecular mechanism and clinical outcomes are separate parts of the explanation. Sources are in the figure.
Primary research: pmc.ncbi.nlm.nih.gov/article…
ALT Six-panel schematic of daraxonrasib action. Active RAS-GTP recruits RAF to activate MEK and ERK. Daraxonrasib enters the cell and binds cyclophilin A. The drug-CypA complex engages active RAS, forming a three-part complex that obstructs effector binding. Downstream growth signaling can decrease. Gold represents RAS, teal CypA, and magenta daraxonrasib. References appear below. The illustration is not to scale and does not predict clinical response.
A living cell. A targeted attack.
Watch a CD19-directed CAR T cell recognize its target, activate and release cytotoxic granules toward the contact.
19 seconds inside the mechanism. Independent illustration.
cellularstories.com